{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:23:22Z","timestamp":1790083402015,"version":"4.0.1"},"reference-count":243,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2021-12372019"],"award-info":[{"award-number":["GR-2021-12372019"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07471-6","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:14:54Z","timestamp":1764155694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biomarkers for Lewy body diseases and other alpha-synucleinopathies in biofluids: current evidence and future directions"],"prefix":"10.1186","volume":"24","author":[{"given":"Alice","family":"Russotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Longobardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ciullini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Angelo","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Beg\u00fcm","family":"Bac\u0131no\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Borroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ghidoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Moda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8618-4282","authenticated-orcid":false,"given":"Claudia","family":"Saraceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"7471_CR1","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","volume":"21","author":"C Soto","year":"2018","unstructured":"Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21:1332\u201340.","journal-title":"Nat Neurosci"},{"key":"7471_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener. 2021;16:83.","journal-title":"Mol Neurodegener"},{"key":"7471_CR3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1126\/science.282.5391.1075","volume":"282","author":"J Hardy","year":"1998","unstructured":"Hardy J, Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science. 1998;282:1075\u20139.","journal-title":"Science"},{"key":"7471_CR4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1750-3639.1999.tb00553.x","volume":"9","author":"DW Dickson","year":"1999","unstructured":"Dickson DW, Lin W, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 1999;9:721\u201332.","journal-title":"Brain Pathol"},{"key":"7471_CR5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/sj.mp.4000458","volume":"3","author":"M Goedert","year":"1998","unstructured":"Goedert M, Spillantini MG. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry. 1998;3:462\u20135.","journal-title":"Mol Psychiatry"},{"issue":"Suppl 5","key":"7471_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00415-008-5004-3","volume":"255","author":"G Alves","year":"2008","unstructured":"Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of parkinson\u2019s disease. J Neurol. 2008;255(Suppl 5):18\u201332.","journal-title":"J Neurol"},{"key":"7471_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27:27\u201342.","journal-title":"Eur J Neurol"},{"key":"7471_CR8","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1007\/s12035-021-02500-z","volume":"58","author":"Y Gopar-Cuevas","year":"2021","unstructured":"Gopar-Cuevas Y, Duarte-Jurado AP, Diaz-Perez RN, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A. Pursuing multiple biomarkers for early idiopathic parkinson\u2019s disease diagnosis. Mol Neurobiol. 2021;58:5517\u201332.","journal-title":"Mol Neurobiol"},{"key":"7471_CR9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/7854_2014_317","volume":"22","author":"SA Schneider","year":"2015","unstructured":"Schneider SA, Obeso JA. Clinical and pathological features of parkinson\u2019s disease. Curr Top Behav Neurosci. 2015;22:205\u201320.","journal-title":"Curr Top Behav Neurosci"},{"key":"7471_CR10","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet. 2021;397:2284\u2013303.","journal-title":"Lancet"},{"key":"7471_CR11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10072-019-04165-y","volume":"41","author":"Y Wu","year":"2020","unstructured":"Wu Y, Yao Q, Jiang G, Wang G, Cheng Q. Identification of distinct blood-based biomarkers in early stage of parkinson\u2019s disease. Neurol Sci. 2020;41:893\u2013901.","journal-title":"Neurol Sci"},{"key":"7471_CR12","doi-asserted-by":"crossref","unstructured":"Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl. 2006:9\u201315.","DOI":"10.1007\/978-3-211-45295-0_3"},{"key":"7471_CR13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","volume":"9","author":"M Goedert","year":"2013","unstructured":"Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of lewy pathology. Nat Rev Neurol. 2013;9:13\u201324.","journal-title":"Nat Rev Neurol"},{"key":"7471_CR14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00401-008-0347-5","volume":"115","author":"KA Jellinger","year":"2008","unstructured":"Jellinger KA, Attems J. Prevalence and impact of vascular and alzheimer pathologies in lewy body disease. Acta Neuropathol. 2008;115:427\u201336.","journal-title":"Acta Neuropathol"},{"key":"7471_CR15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ana.23586","volume":"71","author":"S Rayaprolu","year":"2012","unstructured":"Rayaprolu S, Soto-Ortolaza A, Rademakers R, Uitti RJ, Wszolek ZK, Ross OA. Angiogenin variation and Parkinson disease. Ann Neurol. 2012;71:725\u20138.","journal-title":"Ann Neurol"},{"key":"7471_CR16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00401-003-0676-3","volume":"105","author":"KA Jellinger","year":"2003","unstructured":"Jellinger KA. Prevalence of cerebrovascular lesions in parkinson\u2019s disease. A postmortem study. Acta Neuropathol. 2003;105:415\u20139.","journal-title":"Acta Neuropathol"},{"key":"7471_CR17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2010.07112.x","volume":"116","author":"TU Steidinger","year":"2011","unstructured":"Steidinger TU, Standaert DG, Yacoubian TA. A neuroprotective role for angiogenin in models of parkinson\u2019s disease. J Neurochem. 2011;116:334\u201341.","journal-title":"J Neurochem"},{"key":"7471_CR18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41401-020-0375-9","volume":"41","author":"JHM Prehn","year":"2020","unstructured":"Prehn JHM, Jirstr\u00f6m E. Angiogenin and tRNA fragments in parkinson\u2019s disease and neurodegeneration. Acta Pharmacol Sin. 2020;41:442\u20136.","journal-title":"Acta Pharmacol Sin"},{"key":"7471_CR19","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with parkinson\u2019s disease. Mov Disord. 2007;22:1689\u2013707. quiz 1837.","journal-title":"Mov Disord"},{"key":"7471_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41531-019-0106-4","volume":"6","author":"JYY Szeto","year":"2020","unstructured":"Szeto JYY, Walton CC, Rizos A, Martinez-Martin P, Halliday GM, Naismith SL, Chaudhuri KR, Lewis SJG. Dementia in long-term parkinson\u2019s disease patients: a multicentre retrospective study. NPJ Parkinsons Dis. 2020;6:2.","journal-title":"NPJ Parkinsons Dis"},{"key":"7471_CR21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O\u2019Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"7471_CR22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor J, Thomas A, Attems J, McKeith I. Dementia with lewy bodies: an update and outlook. Mol Neurodegener. 2019;14:5.","journal-title":"Mol Neurodegener"},{"key":"7471_CR23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","volume":"16","author":"KA Jellinger","year":"2018","unstructured":"Jellinger KA, Korczyn AD. Are dementia with lewy bodies and parkinson\u2019s disease dementia the same disease? BMC Med. 2018;16:34.","journal-title":"BMC Med"},{"key":"7471_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","volume":"99","author":"G Bellomo","year":"2022","unstructured":"Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L. \u03b1-Synuclein seed amplification assays for diagnosing synucleinopathies. Way Forw Neurology. 2022;99:195\u2013205.","journal-title":"Way Forw Neurology"},{"key":"7471_CR25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT. Parkinson\u2019s disease and parkinsonism. Am J Med. 2019;132:802\u20137.","journal-title":"Am J Med"},{"key":"7471_CR26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/archneur.56.12.1441","volume":"56","author":"MF Weiner","year":"1999","unstructured":"Weiner MF. Dementia associated with lewy bodies: dilemmas and directions. Arch Neurol. 1999;56:1441\u20132.","journal-title":"Arch Neurol"},{"key":"7471_CR27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp.52.Suppl.78","volume":"Suppl","author":"N Quinn","year":"1989","unstructured":"Quinn N. Multiple system atrophy\u2013the nature of the Beast. J Neurol Neurosurg Psychiatry. 1989;Suppl:78\u201389.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7471_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870120203","volume":"12","author":"GK Wenning","year":"1997","unstructured":"Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12:133\u201347.","journal-title":"Mov Disord"},{"key":"7471_CR29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-510X(98)00304-9","volume":"163","author":"S Gilman","year":"1999","unstructured":"Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163:94\u20138.","journal-title":"J Neurol Sci"},{"key":"7471_CR30","doi-asserted-by":"crossref","unstructured":"Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, Frick C, Ndayisaba J, Ulmer H, Pellecchia MT, Barone P, Kim HT, Hooker J, Quinn NP, Cardozo A, Tolosa E, Abele M, Klockgether T, \u00d8stergaard K, Dupont E, Schimke N, Eggert KM, Oertel W, Djaldetti R, Poewe W. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA study group (EMSA SG). Mov Disord. 2006;21:179\u201386.","DOI":"10.1002\/mds.20678"},{"key":"7471_CR31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0022-510X(89)90219-0","volume":"94","author":"MI Papp","year":"1989","unstructured":"Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989;94:79\u2013100.","journal-title":"J Neurol Sci"},{"key":"7471_CR32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-3940(98)00504-7","volume":"251","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with parkinson\u2019s disease and dementia with lewy bodies. Neurosci Lett. 1998;251:205\u20138.","journal-title":"Neurosci Lett"},{"key":"7471_CR33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jnnp.2005.073528","volume":"77","author":"T Ozawa","year":"2006","unstructured":"Ozawa T, Healy DG, Abou-Sleiman PM, Ahmadi KR, Quinn N, Lees AJ, Shaw K, Wullner U, Berciano J, Moller JC, Kamm C, Burk K, Josephs KA, Barone P, Tolosa E, Goldstein DB, Wenning G, Geser F, Holton JL, Gasser T, Revesz T, Wood NW. The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2006;77:464\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7471_CR34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","volume":"372","author":"A Fanciulli","year":"2015","unstructured":"Fanciulli A, Wenning GK. Multiple-System atrophy. N Engl J Med. 2015;372:249\u201363.","journal-title":"N Engl J Med"},{"key":"7471_CR35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/mds.25880","volume":"29","author":"I Stankovic","year":"2014","unstructured":"Stankovic I, Krismer F, Jesic A, Antonini A, Benke T, Brown RG, Burn DJ, Holton JL, Kaufmann H, Kostic VS, Ling H, Meissner WG, Poewe W, Semnic M, Seppi K, Takeda A, Weintraub D, Wenning GK. Cognitive impairment in multiple system atrophy: a position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Mov Disord. 2014;29:857\u201367.","journal-title":"Mov Disord"},{"key":"7471_CR36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/CON.0000000000000348","volume":"22","author":"NR McFarland","year":"2016","unstructured":"McFarland NR. Diagnostic approach to atypical parkinsonian syndromes. Continuum (Minneap Minn). 2016;22:1117\u201342.","journal-title":"Continuum (Minneap Minn)"},{"key":"7471_CR37","doi-asserted-by":"crossref","first-page":"a009258","DOI":"10.1101\/cshperspect.a009258","volume":"2","author":"DW Dickson","year":"2012","unstructured":"Dickson DW. Parkinson\u2019s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2:a009258.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"7471_CR38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","volume":"10","author":"JC Steele","year":"1964","unstructured":"Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333\u201359.","journal-title":"Arch Neurol"},{"issue":"Pt 4","key":"7471_CR39","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/brain\/119.4.1137","volume":"119","author":"T Revesz","year":"1996","unstructured":"Revesz T, Sangha H, Daniel SE. The nucleus Raphe interpositus in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Brain. 1996;119(Pt 4):1137\u201343.","journal-title":"Brain"},{"key":"7471_CR40","doi-asserted-by":"crossref","unstructured":"Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson\u2019s syndrome and PSP-parkinsonism. Brain. 2005;128:1247\u201358.","DOI":"10.1093\/brain\/awh488"},{"key":"7471_CR41","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2990.2003.00463.x","volume":"29","author":"R de Silva","year":"2003","unstructured":"de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Utton M, Strand C, Jowett T, Khan N, Anderton B, Wood N, Holton J, Revesz T, Lees A. Pathological inclusion bodies in Tauopathies contain distinct complements of Tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol. 2003;29:288\u2013302.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"7471_CR42","first-page":"1388","volume":"146","author":"MB Feany","year":"1995","unstructured":"Feany MB, Dickson DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol. 1995;146:1388\u201396.","journal-title":"Am J Pathol"},{"key":"7471_CR43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/cxo.12429","volume":"99","author":"RA Armstrong","year":"2016","unstructured":"Armstrong RA. Visual signs and symptoms of corticobasal degeneration. Clin Exp Optom. 2016;99:498\u2013506.","journal-title":"Clin Exp Optom"},{"key":"7471_CR44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1212\/WNL.48.1.119","volume":"48","author":"I Litvan","year":"1997","unstructured":"Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, Lai EC, Verny M, Ray-Chaudhuri K, McKee A, Jellinger K, Pearce RK, Bartko JJ. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997;48:119\u201325.","journal-title":"Neurology"},{"key":"7471_CR45","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.53.4.795","volume":"53","author":"BF Boeve","year":"1999","unstructured":"Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ, Dickson DW, Kokmen E, Petersen RC. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology. 1999;53:795\u2013800.","journal-title":"Neurology"},{"key":"7471_CR46","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1002\/mds.28738","volume":"36","author":"I Schulz","year":"2021","unstructured":"Schulz I, Kruse N, Gera RG, Kremer T, Cedarbaum J, Barbour R, Zago W, Schade S, Otte B, Bartl M, Hutten SJ, Trenkwalder C, Mollenhauer B. Systematic assessment of 10 biomarker candidates focusing on \u03b1-Synuclein-Related disorders. Mov Disord. 2021;36:2874\u201387.","journal-title":"Mov Disord"},{"key":"7471_CR47","doi-asserted-by":"crossref","first-page":"e1001604","DOI":"10.1371\/journal.pbio.1001604","volume":"11","author":"C Fr\u00fchbeis","year":"2013","unstructured":"Fr\u00fchbeis C, Fr\u00f6hlich D, Kuo WP, Amphornrat J, Thilemann S, Saab AS, Kirchhoff F, M\u00f6bius W, Goebbels S, Nave K, Schneider A, Simons M, Klugmann M, Trotter J, Kr\u00e4mer-Albers E. Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol. 2013;11:e1001604.","journal-title":"PLoS Biol"},{"key":"7471_CR48","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/mds.28639","volume":"36","author":"A Stuendl","year":"2021","unstructured":"Stuendl A, Kraus T, Chatterjee M, Zapke B, Sadowski B, Moebius W, Hobert MA, Deuschle C, Brockmann K, Maetzler W, Mollenhauer B, Schneider A. \u03b1-Synuclein in Plasma-Derived extracellular vesicles is a potential biomarker of parkinson\u2019s disease. Mov Disord. 2021;36:2508\u201318.","journal-title":"Mov Disord"},{"key":"7471_CR49","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","volume":"91","author":"C Jiang","year":"2020","unstructured":"Jiang C, Hopfner F, Katsikoudi A, Hein R, Catli C, Evetts S, Huang Y, Wang H, Ryder JW, Kuhlenbaeumer G, Deuschl G, Padovani A, Berg D, Borroni B, Hu MT, Davis JJ, Tofaris GK. Serum neuronal exosomes predict and differentiate parkinson\u2019s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2020;91:720\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7471_CR50","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","volume":"25","author":"H Lee","year":"2005","unstructured":"Lee H, Patel S, Lee S. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005;25:6016\u201324.","journal-title":"J Neurosci"},{"key":"7471_CR51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40478-017-0445-5","volume":"5","author":"J Ngolab","year":"2017","unstructured":"Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, Masliah D, Adame A, Masliah E, Rissman RA. Brain-derived exosomes from dementia with lewy bodies propagate \u03b1-synuclein pathology. Acta Neuropathol Commun. 2017;5:46.","journal-title":"Acta Neuropathol Commun"},{"key":"7471_CR52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-5793(94)00395-5","volume":"345","author":"R Jakes","year":"1994","unstructured":"Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994;345:27\u201332.","journal-title":"FEBS Lett"},{"key":"7471_CR53","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1007\/s12035-017-0845-3","volume":"55","author":"K Chang","year":"2018","unstructured":"Chang K, Cheng M, Tang H, Huang C, Wu Y, Chen C. Alternations of metabolic profile and kynurenine metabolism in the plasma of parkinson\u2019s disease. Mol Neurobiol. 2018;55:6319\u201328.","journal-title":"Mol Neurobiol"},{"key":"7471_CR54","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/prot.24043","volume":"80","author":"A Binolfi","year":"2012","unstructured":"Binolfi A, Fern\u00e1ndez CO, Sica MP, Delfino JM, Santos J. Recognition between a short unstructured peptide and a partially folded fragment leads to the thioredoxin fold sharing native-like dynamics. Proteins. 2012;80:1448\u201364.","journal-title":"Proteins"},{"key":"7471_CR55","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1038\/nature12125","volume":"498","author":"J Burr\u00e9","year":"2013","unstructured":"Burr\u00e9 J, Vivona S, Diao J, Sharma M, Brunger AT, S\u00fcdhof TC. Properties of native brain \u03b1-synuclein. Nature. 2013;498:E4\u20137.","journal-title":"Nature"},{"key":"7471_CR56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels T, Choi JG, Selkoe DJ. \u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107\u201310.","journal-title":"Nature"},{"key":"7471_CR57","doi-asserted-by":"crossref","first-page":"17797","DOI":"10.1073\/pnas.1113260108","volume":"108","author":"W Wang","year":"2011","unstructured":"Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LTT, Liao J, Auclair JR, Johnson D, Landeru A, Simorellis AK, Ju S, Cookson MR, Asturias FJ, Agar JN, Webb BN, Kang C, Ringe D, Petsko GA, Pochapsky TC, Hoang QQ. A soluble \u03b1-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A. 2011;108:17797\u2013802.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7471_CR58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14:38\u201348.","journal-title":"Nat Rev Neurosci"},{"key":"7471_CR59","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1523\/JNEUROSCI.5368-11.2012","volume":"32","author":"E Colla","year":"2012","unstructured":"Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic \u03b1-synuclein oligomer within Endoplasmic reticulum occurs in \u03b1-synucleinopathy in vivo. J Neurosci. 2012;32:3301\u20135.","journal-title":"J Neurosci"},{"key":"7471_CR60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi JC, Hirth F. Mechanisms of \u03b1-Synuclein induced synaptopathy in parkinson\u2019s disease. Front Neurosci. 2018;12:80.","journal-title":"Front Neurosci"},{"key":"7471_CR61","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burr\u00e9","year":"2010","unstructured":"Burr\u00e9 J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, S\u00fcdhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663\u20137.","journal-title":"Science"},{"key":"7471_CR62","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u20134.","journal-title":"Nat Cell Biol"},{"key":"7471_CR63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","volume":"109","author":"EM Rocha","year":"2018","unstructured":"Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in parkinson\u2019s disease. Neurobiol Dis. 2018;109:249\u201357.","journal-title":"Neurobiol Dis"},{"key":"7471_CR64","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awq008","volume":"133","author":"Z Hong","year":"2010","unstructured":"Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of parkinson\u2019s disease. Brain. 2010;133:713\u201326.","journal-title":"Brain"},{"key":"7471_CR65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-D\u00f6ring F, Trenkwalder C, Schlossmacher MG. \u03b1-Synuclein and Tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230\u201340.","journal-title":"Lancet Neurol"},{"key":"7471_CR66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","volume":"349","author":"T Tokuda","year":"2006","unstructured":"Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OMA. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with parkinson\u2019s disease. Biochem Biophys Res Commun. 2006;349:162\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"7471_CR67","doi-asserted-by":"crossref","first-page":"e0123162","DOI":"10.1371\/journal.pone.0123162","volume":"10","author":"R Ishii","year":"2015","unstructured":"Ishii R, Tokuda T, Tatebe H, Ohmichi T, Kasai T, Nakagawa M, Mizuno T, El-Agnaf OMA. Decrease in plasma levels of \u03b1-synuclein is evident in patients with parkinson\u2019s disease after elimination of heterophilic antibody interference. PLoS ONE. 2015;10:e0123162.","journal-title":"PLoS ONE"},{"key":"7471_CR68","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1093\/brain\/awr015","volume":"134","author":"I Devic","year":"2011","unstructured":"Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J. Salivary \u03b1-synuclein and DJ-1: potential biomarkers for parkinson\u2019s disease. Brain. 2011;134:e178.","journal-title":"Brain"},{"key":"7471_CR69","first-page":"e29880","volume":"14","author":"P Muddaloor","year":"2022","unstructured":"Muddaloor P, Farinango M, Ansary A, Dakka A, Nazir Z, Shamim H, Jean M, Umair M, Khan S. Prospect of Alpha-Synuclein (A-Syn) isolation from saliva as a promising diagnostic biomarker alternative in parkinson\u2019s disease (PD). Syst Rev Cureus. 2022;14:e29880.","journal-title":"Syst Rev Cureus"},{"key":"7471_CR70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/19768354.2021.1883735","volume":"25","author":"D Nam","year":"2021","unstructured":"Nam D, Kim A, Han SJ, Lee S, Park S, Seol W, Son I, Ho DH. Analysis of \u03b1-synuclein levels related to LRRK2 kinase activity: from substantia Nigra to urine of patients with parkinson\u2019s disease. Anim Cells Syst (Seoul). 2021;25:28\u201336.","journal-title":"Anim Cells Syst (Seoul)"},{"key":"7471_CR71","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/bmm-2019-0167","volume":"13","author":"SF Hamm-Alvarez","year":"2019","unstructured":"Hamm-Alvarez SF, Okamoto CT, Janga SR, Feigenbaum D, Edman MC, Freire D, Shah M, Ghanshani R, Mack WJ, Lew MF. Oligomeric \u03b1-synuclein is increased in basal tears of parkinson\u2019s patients. Biomark Med. 2019;13:941\u201352.","journal-title":"Biomark Med"},{"key":"7471_CR72","first-page":"1","volume":"78","author":"Z Wang","year":"2020","unstructured":"Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orr\u00fa CD, Tatsuoka C, Liguori R, Gunzler SA, Caughey B, Jimenez-Capdeville ME, Zhu X, Doppler K, Cui L, Chen SG, Ma J, Zou W. Skin \u03b1-Synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol. 2020;78:1\u201311.","journal-title":"JAMA Neurol"},{"key":"7471_CR73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/mds.26473","volume":"31","author":"SJ Chung","year":"2016","unstructured":"Chung SJ, Kim J, Lee HJ, Ryu H, Kim K, Lee JH, Jung KW, Kim MJ, Kim M, Kim YJ, Yun S, Lee J, Hong S, Myung S. Alpha-synuclein in gastric and colonic mucosa in parkinson\u2019s disease: limited role as a biomarker. Mov Disord. 2016;31:241\u20139.","journal-title":"Mov Disord"},{"key":"7471_CR74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0304-3940(98)00599-0","volume":"253","author":"MW Jakowec","year":"1998","unstructured":"Jakowec MW, Petzinger GM, Sastry S, Donaldson DM, McCormack A, Langston JW. The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with parkinson\u2019s disease or normal controls. Neurosci Lett. 1998;253:13\u20136.","journal-title":"Neurosci Lett"},{"key":"7471_CR75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0304-3940(00)01153-8","volume":"287","author":"R Borghi","year":"2000","unstructured":"Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, Abbruzzese G, Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from parkinson\u2019s disease and normal subjects. Neurosci Lett. 2000;287:65\u20137.","journal-title":"Neurosci Lett"},{"key":"7471_CR76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","volume":"213","author":"B Mollenhauer","year":"2008","unstructured":"Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel J, Locascio JJ, El-Agnaf OMA, Schlossmacher MG. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213:315\u201325.","journal-title":"Exp Neurol"},{"key":"7471_CR77","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ana.25447","volume":"85","author":"A van Rumund","year":"2019","unstructured":"van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM. \u03b1-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann Neurol. 2019;85:777\u201381.","journal-title":"Ann Neurol"},{"key":"7471_CR78","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1353-8020(13)70020-8","volume":"20","author":"B Mollenhauer","year":"2014","unstructured":"Mollenhauer B. Quantification of \u03b1-synuclein in cerebrospinal fluid: how ideal is this biomarker for parkinson\u2019s disease? Parkinsonism Relat Disord. 2014;20:S76\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"7471_CR79","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","volume":"450","author":"A Ohrfelt","year":"2009","unstructured":"Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse. loss? Neurosci Lett. 2009;450:332\u20135.","journal-title":"loss? Neurosci Lett"},{"key":"7471_CR80","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","volume":"75","author":"T Tokuda","year":"2010","unstructured":"Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SS, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OMA. Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75:1766\u201372.","journal-title":"Neurology"},{"key":"7471_CR81","doi-asserted-by":"crossref","unstructured":"Zhou B, Wen M, Yu W, Zhang C, Jiao L. The diagnostic and differential diagnosis utility of cerebrospinal fluid \u03b1-synuclein levels in parkinson\u2019s disease: a meta-analysis. Parkinson\u2019s Disease. 2015;2015:567386.","DOI":"10.1155\/2015\/567386"},{"key":"7471_CR82","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2012.11.004","volume":"532","author":"B Mollenhauer","year":"2013","unstructured":"Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-D\u00f6ring F, Ebentheuer J, Trenkwalder C, Schlossmacher MG. Total CSF \u03b1-synuclein is lower in de Novo Parkinson patients than in healthy subjects. Neurosci Lett. 2013;532:44\u20138.","journal-title":"Neurosci Lett"},{"key":"7471_CR83","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.nbd.2011.08.003","volume":"45","author":"PG Foulds","year":"2012","unstructured":"Foulds PG, Yokota O, Thurston A, Davidson Y, Ahmed Z, Holton J, Thompson JC, Akiyama H, Arai T, Hasegawa M, Gerhard A, Allsop D, Mann DMA. Post mortem cerebrospinal fluid \u03b1-synuclein levels are Raised in multiple system atrophy and distinguish this from the other \u03b1-synucleinopathies, parkinson\u2019s disease and dementia with lewy bodies. Neurobiol Dis. 2012;45:188\u201395.","journal-title":"Neurobiol Dis"},{"key":"7471_CR84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S, Safieh-Garabedian B, Tokuda T, Teunissen CE, Berendse HW, van de Berg WDJ, El-Agnaf OMA. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for parkinson\u2019s disease. Mol Neurodegener. 2016;11:7.","journal-title":"Mol Neurodegener"},{"key":"7471_CR85","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm.2294","volume":"17","author":"R Atarashi","year":"2011","unstructured":"Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, Ishibashi D, Matsubara T, Nakagaki T, Yamanaka H, Shirabe S, Yamada M, Mizusawa H, Kitamoto T, Klug G, McGlade A, Collins SJ, Nishida N. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011;17:175\u20138.","journal-title":"Nat Med"},{"key":"7471_CR86","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jsb.2005.06.006","volume":"151","author":"R Khurana","year":"2005","unstructured":"Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, Roy R, Singh S. Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol. 2005;151:229\u201338.","journal-title":"J Struct Biol"},{"key":"7471_CR87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41531-021-00232-4","volume":"7","author":"C Quadalti","year":"2021","unstructured":"Quadalti C, Calandra-Buonaura G, Baiardi S, Mastrangelo A, Rossi M, Zenesini C, Giannini G, Candelise N, Sambati L, Polischi B, Plazzi G, Capellari S, Cortelli P, Parchi P. Neurofilament light chain and \u03b1-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. NPJ Parkinsons Dis. 2021;7:93.","journal-title":"NPJ Parkinsons Dis"},{"key":"7471_CR88","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.25824","volume":"88","author":"W Singer","year":"2020","unstructured":"Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Boeve BF, Sletten DM, Gehrking TL, Gehrking JA, Olson AD, Savica R, Suarez MD, Soto C, Low PA. Alpha-Synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from lewy body synucleinopathies. Ann Neurol. 2020;88:503\u201312.","journal-title":"Ann Neurol"},{"key":"7471_CR89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orr\u00f9 CD, Antelmi E, Mammana A, Hughson AG, Calandra-Buonaura G, Ladogana A, Plazzi G, Cortelli P, Caughey B, Parchi P. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for lewy body-associated synucleinopathies. Acta Neuropathol. 2020;140:49\u201362.","journal-title":"Acta Neuropathol"},{"key":"7471_CR90","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, Joachim C, Esiri M, Evetts SG, Rolinski M, Baig F, Ruffmann C, Wade-Martins R, Hu MTM, Parkkinen L, Green AJE. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3:812\u20138.","journal-title":"Ann Clin Transl Neurol"},{"key":"7471_CR91","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ, Green A, Soto C. Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of parkinson\u2019s disease. Mov Disord. 2019;34:536\u201344.","journal-title":"Mov Disord"},{"key":"7471_CR92","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, Hu B, Schmeichel A, Singer W, Wu G, Tsai A, Shirani H, Nilsson KPR, Low PA, Soto C. Discriminating \u03b1-synuclein strains in parkinson\u2019s disease and multiple system atrophy. Nature. 2020;578:273\u20137.","journal-title":"Nature"},{"key":"7471_CR93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","volume":"480","author":"M Shi","year":"2010","unstructured":"Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in parkinson\u2019s disease. Neurosci Lett. 2010;480:78\u201382.","journal-title":"Neurosci Lett"},{"key":"7471_CR94","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00702-019-02137-2","volume":"127","author":"A Bougea","year":"2020","unstructured":"Bougea A, Stefanis L, Emmanouilidou E, Vekrelis K, Kapaki E. High discriminatory ability of peripheral and CFSF biomarkers in lewy body diseases. J Neural Transm (Vienna). 2020;127:311\u201322.","journal-title":"J Neural Transm (Vienna)"},{"key":"7471_CR95","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mds.22928","volume":"25","author":"R Duran","year":"2010","unstructured":"Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F. Plasma alpha-synuclein in patients with parkinson\u2019s disease with and without treatment. Mov Disord. 2010;25:489\u201393.","journal-title":"Mov Disord"},{"key":"7471_CR96","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s12031-022-01984-1","volume":"72","author":"A Ghit","year":"2022","unstructured":"Ghit A, Deeb HE. Cytokines, miRNAs, and antioxidants as combined Non-invasive biomarkers for parkinson\u2019s disease. J Mol Neurosci. 2022;72:1133\u201340.","journal-title":"J Mol Neurosci"},{"key":"7471_CR97","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/acschemneuro.7b00063","volume":"8","author":"I Horvath","year":"2017","unstructured":"Horvath I, Iashchishyn IA, Forsgren L, Morozova-Roche LA. Immunochemical detection of \u03b1-Synuclein autoantibodies in parkinson\u2019s disease: correlation between plasma and cerebrospinal fluid levels. ACS Chem Neurosci. 2017;8:1170\u20136.","journal-title":"ACS Chem Neurosci"},{"key":"7471_CR98","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","volume":"113","author":"PH Lee","year":"2006","unstructured":"Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with parkinson\u2019s disease and multiple system atrophy. J Neural Transm (Vienna). 2006;113:1435\u20139.","journal-title":"J Neural Transm (Vienna)"},{"key":"7471_CR99","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","volume":"15","author":"ASL Ng","year":"2020","unstructured":"Ng ASL, Tan YJ, Yong ACW, Saffari SE, Lu Z, Ng EY, Ng SYE, Chia NSY, Choi X, Heng D, Neo S, Xu Z, Keong NCH, Tay KY, Au WL, Tan LCS, Tan E. Utility of plasma neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early parkinson\u2019s disease. Mol Neurodegener. 2020;15:33.","journal-title":"Mol Neurodegener"},{"key":"7471_CR100","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000506480","volume":"19","author":"L Wang","year":"2019","unstructured":"Wang L, Wang G, Duan Y, Wang F, Lin S, Zhang F, Li H, Li A, Li H. A comparative study of the diagnostic potential of plasma and erythrocytic \u03b1-Synuclein in parkinson\u2019s disease. Neurodegener Dis. 2019;19:204\u201310.","journal-title":"Neurodegener Dis"},{"key":"7471_CR101","doi-asserted-by":"crossref","first-page":"e52312","DOI":"10.1371\/journal.pone.0052312","volume":"7","author":"A Gorostidi","year":"2012","unstructured":"Gorostidi A, Bergareche A, Ruiz-Mart\u00ednez J, Mart\u00ed-Mass\u00f3 JF, Cruz M, Varghese S, Qureshi MM, Alzahmi F, Al-Hayani A. L\u00f3pez de Mun\u00e1in A, El-Agnaf OMA: \u0391lpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS ONE. 2012;7:e52312.","journal-title":"PLoS ONE"},{"key":"7471_CR102","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","volume":"204","author":"Q Li","year":"2007","unstructured":"Li Q, Mok SS, Laughton KM, McLean CA, Cappai R, Masters CL, Culvenor JG, Horne MK. Plasma alpha-synuclein is decreased in subjects with parkinson\u2019s disease. Exp Neurol. 2007;204:583\u20138.","journal-title":"Exp Neurol"},{"key":"7471_CR103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-019-00052-x","volume":"16","author":"KH Shim","year":"2020","unstructured":"Shim KH, Kim SC, Youn YC, Sung Y, An S. Decreased plasma \u03b1-synuclein in idiopathic parkinson\u2019s disease patients after adjusting hemolysis factor. Mol Cell Toxicol. 2020;16:1\u20138.","journal-title":"Mol Cell Toxicol"},{"key":"7471_CR104","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.dib.2016.11.089","volume":"10","author":"A Emelyanov","year":"2017","unstructured":"Emelyanov A, Andoskin P, Pchelina S. Dataset of total, oligomeric alpha-synuclein and hemoglobin levels in plasma in Parkinson\u05f3s disease. Data Brief. 2017;10:182\u20135.","journal-title":"Data Brief"},{"key":"7471_CR105","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.3389\/fimmu.2019.02253","volume":"10","author":"J Folke","year":"2019","unstructured":"Folke J, Rydbirk R, L\u00f8kkegaard A, Salvesen L, Hejl A, Starhof C, Bech S, Winge K, Christensen S, Pedersen L\u00d8, Aznar S, Pakkenberg B, Brudek T. Distinct autoimmune Anti-\u03b1-Synuclein antibody patterns in multiple system atrophy and parkinson\u2019s disease. Front Immunol. 2019;10:2253.","journal-title":"Front Immunol"},{"key":"7471_CR106","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/mds.27232","volume":"33","author":"JG Goldman","year":"2018","unstructured":"Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Saint-Hilaire M, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K, Kang UJ. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and parkinson\u2019s disease features. Mov Disord. 2018;33:282\u20138.","journal-title":"Mov Disord"},{"key":"7471_CR107","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1096\/fj.03-1449com","volume":"20","author":"OMA El-Agnaf","year":"2006","unstructured":"El-Agnaf OMA, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for parkinson\u2019s disease. FASEB J. 2006;20:419\u201325.","journal-title":"FASEB J"},{"key":"7471_CR108","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1096\/fj.10-179192","volume":"25","author":"PG Foulds","year":"2011","unstructured":"Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, Hasegawa M, Taylor M, Mann D, Allsop D. Phosphorylated \u03b1-synuclein can be detected in blood plasma and is potentially a useful biomarker for parkinson\u2019s disease. FASEB J. 2011;25:4127\u201337.","journal-title":"FASEB J"},{"key":"7471_CR109","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P. CSF and blood biomarkers for parkinson\u2019s disease. Lancet Neurol. 2019;18:573\u201386.","journal-title":"Lancet Neurol"},{"key":"7471_CR110","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jnc.14809","volume":"150","author":"M Fayyad","year":"2019","unstructured":"Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, El-Agnaf OMA. Parkinson\u2019s disease biomarkers based on \u03b1-synuclein. J Neurochem. 2019;150:626\u201336.","journal-title":"J Neurochem"},{"key":"7471_CR111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pjnns.2017.11.009","volume":"52","author":"M Malec-Litwinowicz","year":"2018","unstructured":"Malec-Litwinowicz M, Plewka A, Plewka D, Bogunia E, Morek M, Szczudlik A, Szubiga M, Rudzi\u0144ska-Bar M. The relation between plasma \u03b1-synuclein level and clinical symptoms or signs of parkinson\u2019s disease. Neurol Neurochir Pol. 2018;52:243\u201351.","journal-title":"Neurol Neurochir Pol"},{"key":"7471_CR112","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3389\/fnins.2019.00889","volume":"13","author":"C Cariulo","year":"2019","unstructured":"Cariulo C, Martufi P, Verani M, Azzollini L, Bruni G, Weiss A, Deguire SM, Lashuel HA, Scaricamazza E, Sancesario GM, Schirinzi T, Mercuri NB, Sancesario G, Caricasole A, Petricca L. Phospho-S129 Alpha-Synuclein is present in human plasma but not in cerebrospinal fluid as determined by an ultrasensitive immunoassay. Front Neurosci. 2019;13:889.","journal-title":"Front Neurosci"},{"key":"7471_CR113","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/srep02540","volume":"3","author":"PG Foulds","year":"2013","unstructured":"Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, Mann DMA, Allsop D. A longitudinal study on \u03b1-synuclein in blood plasma as a biomarker for parkinson\u2019s disease. Sci Rep. 2013;3:2540.","journal-title":"Sci Rep"},{"key":"7471_CR114","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3390\/jcm8101601","volume":"8","author":"C Lin","year":"2019","unstructured":"Lin C, Liu H, Yang S, Yang K, Wu C, Chiu M. Plasma pS129-\u03b1-Synuclein is a surrogate biofluid marker of motor severity and progression in parkinson\u2019s disease. J Clin Med. 2019;8:1601.","journal-title":"J Clin Med"},{"key":"7471_CR115","doi-asserted-by":"crossref","first-page":"869797","DOI":"10.3389\/fnagi.2022.869797","volume":"14","author":"X Zhao","year":"2022","unstructured":"Zhao X, He H, Xiong X, Ye Q, Feng F, Zhou S, Chen W, Xia K, Qian S, Yang Y, Xie C. Lewy Body-Associated proteins A-Synuclein (a-syn) as a Plasma-Based biomarker for parkinson\u2019s disease. Front Aging Neurosci. 2022;14:869797.","journal-title":"Front Aging Neurosci"},{"key":"7471_CR116","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mds.26463","volume":"31","author":"Y Saito","year":"2016","unstructured":"Saito Y, Shioya A, Sano T, Sumikura H, Murata M, Murayama S. Lewy body pathology involves the olfactory cells in parkinson\u2019s disease and related disorders. Mov Disord. 2016;31:135\u20138.","journal-title":"Mov Disord"},{"key":"7471_CR117","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/mds.22464","volume":"24","author":"M Witt","year":"2009","unstructured":"Witt M, Bormann K, Gudziol V, Pehlke K, Barth K, Minovi A, H\u00e4hner A, Reichmann H, Hummel T. Biopsies of olfactory epithelium in patients with parkinson\u2019s disease. Mov Disord. 2009;24:906\u201314.","journal-title":"Mov Disord"},{"key":"7471_CR118","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00401-008-0450-7","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach TG, White CL, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for lewy body disorders. Acta Neuropathol. 2009;117:169\u201374.","journal-title":"Acta Neuropathol"},{"key":"7471_CR119","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00401-007-0313-7","volume":"115","author":"TG Beach","year":"2008","unstructured":"Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN. Walker DG: reduced striatal tyrosine hydroxylase in incidental lewy body disease. Acta Neuropathol. 2008;115:445\u201351.","journal-title":"Acta Neuropathol"},{"key":"7471_CR120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-019-0164-x","volume":"8","author":"CMG De Luca","year":"2019","unstructured":"De Luca CMG, Elia AE, Portaleone SM, Cazzaniga FA, Rossi M, Bistaffa E, De Cecco E, Narkiewicz J, Salzano G, Carletta O, Romito L, Devigili G, Soliveri P, Tiraboschi P, Legname G, Tagliavini F, Eleopra R, Giaccone G, Moda F. Efficient RT-QuIC seeding activity for \u03b1-synuclein in olfactory mucosa samples of patients with parkinson\u2019s disease and multiple system atrophy. Transl Neurodegener. 2019;8:24.","journal-title":"Transl Neurodegener"},{"key":"7471_CR121","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/brain\/awab005","volume":"144","author":"A Stefani","year":"2021","unstructured":"Stefani A, Iranzo A, Holzknecht E, Perra D, Bongianni M, Gaig C, Heim B, Serradell M, Sacchetto L, Garrido A, Capaldi S, S\u00e1nchez-G\u00f3mez A, Cecchini MP, Mariotto S, Ferrari S, Fiorini M, Schmutzhard J, Cocchiara P, Vilaseca I, Brozzetti L, Monaco S, Jose Marti M, Seppi K, Tolosa E, Santamaria J, H\u00f6gl B, Poewe W, Zanusso G. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain. 2021;144:1118\u201326.","journal-title":"Brain"},{"key":"7471_CR122","doi-asserted-by":"crossref","first-page":"fcab045","DOI":"10.1093\/braincomms\/fcab045","volume":"3","author":"D Perra","year":"2021","unstructured":"Perra D, Bongianni M, Novi G, Janes F, Bessi V, Capaldi S, Sacchetto L, Tagliapietra M, Schenone G, Morbelli S, Fiorini M, Cattaruzza T, Mazzon G, Orr\u00f9 CD, Catalan M, Polverino P, Bernardini A, Pellitteri G, Valente M, Bertolotti C, Nacmias B, Maggiore G, Cavallaro T, Manganotti P, Gigli G, Monaco S, Nobili F, Zanusso G. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with lewy bodies. Brain Commun. 2021;3:fcab045.","journal-title":"Brain Commun"},{"key":"7471_CR123","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-022-00311-3","volume":"11","author":"M Bongianni","year":"2022","unstructured":"Bongianni M, Catalan M, Perra D, Fontana E, Janes F, Bertolotti C, Sacchetto L, Capaldi S, Tagliapietra M, Polverino P, Tommasini V, Bellavita G, Kachoie EA, Baruca R, Bernardini A, Valente M, Fiorini M, Bronzato E, Tamburin S, Bertolasi L, Brozzetti L, Cecchini MP, Gigli G, Monaco S, Manganotti P, Zanusso G. Olfactory swab sampling optimization for \u03b1-synuclein aggregate detection in patients with parkinson\u2019s disease. Transl Neurodegener. 2022;11:37.","journal-title":"Transl Neurodegener"},{"key":"7471_CR124","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13024-021-00491-y","volume":"16","author":"C Bargar","year":"2021","unstructured":"Bargar C, De Luca CMG, Devigili G, Elia AE, Cilia R, Portaleone SM, Wang W, Tramacere I, Bistaffa E, Cazzaniga FA, Felisati G, Legname G, Di Fonzo A, Xu R, Gunzler SA, Giaccone G, Eleopra R, Chen SG, Moda F. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Mol Neurodegener. 2021;16:82.","journal-title":"Mol Neurodegener"},{"key":"7471_CR125","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/ana.21910","volume":"67","author":"SE Arnold","year":"2010","unstructured":"Arnold SE, Lee EB, Moberg PJ, Stutzbach L, Kazi H, Han L, Lee VMY, Trojanowski JQ. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in alzheimer disease. Ann Neurol. 2010;67:462\u20139.","journal-title":"Ann Neurol"},{"key":"7471_CR126","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1586\/14789450.2015.1094380","volume":"12","author":"J Wu","year":"2015","unstructured":"Wu J, Gao Y. Physiological conditions can be reflected in human urine proteome and metabolome. Expert Rev Proteom. 2015;12:623\u201336.","journal-title":"Expert Rev Proteom"},{"key":"7471_CR127","first-page":"57","volume":"25","author":"J Jing","year":"2018","unstructured":"Jing J, Gao Y. Urine biomarkers in the early stages of diseases: current status and perspective. Discov Med. 2018;25:57\u201365.","journal-title":"Discov Med"},{"key":"7471_CR128","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3233\/JPD-201983","volume":"10","author":"D Nam","year":"2020","unstructured":"Nam D, Lee J, Lee M, Kim J, Seol W, Son I, Ho DH. Detection and assessment of \u03b1-Synuclein oligomers in the urine of parkinson\u2019s disease patients. J Parkinsons Dis. 2020;10:981\u201391.","journal-title":"J Parkinsons Dis"},{"key":"7471_CR129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.27250","volume":"98","author":"L M\u00fcller","year":"2025","unstructured":"M\u00fcller L, \u00d6zd\u00fczenciler P, Schedlich-Teufer C, Seger A, Jergas H, Fink GR, Willbold D, Sommerauer M, Barbe MT, Tamg\u00fcney G. Elevated \u03b1-Synuclein aggregate levels in the urine of patients with isolated REM sleep behavior disorder and parkinson\u2019s disease. Ann Neurol. 2025;98:147\u201351.","journal-title":"Ann Neurol"},{"key":"7471_CR130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40478-025-02034-8","volume":"13","author":"R Bsoul","year":"2025","unstructured":"Bsoul R, Mcwilliam OH, Waldemar G, Hasselbalch SG, Simonsen AH, Von Buchwald C, Bech M, Pinborg CH, Pedersen CK, Baungaard SO, Lombard\u00eda J, Ejlerskov P, Bongianni M, Bronzato E, Zanusso G, Frederiksen KS, Lund EL, Are\u0161kevi\u010di\u016bt\u0117 A. Accurate detection of pathologic \u03b1-synuclein in CSF, skin, olfactory mucosa, and urine with a uniform seeding amplification assay. Acta Neuropathol Commun. 2025;13:113.","journal-title":"Acta Neuropathol Commun"},{"key":"7471_CR131","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7471_CR132","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","volume":"233","author":"A Petzold","year":"2005","unstructured":"Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233:183\u201398.","journal-title":"J Neurol Sci"},{"key":"7471_CR133","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577\u201389.","journal-title":"Nat Rev Neurol"},{"key":"7471_CR134","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4137\/JCNSD.S13821","volume":"6","author":"C Hjalmarsson","year":"2014","unstructured":"Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND, Olsson B, Eckerstr\u00f6m C, Bokemark L, Wallin A. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis. 2014;6:51\u20138.","journal-title":"J Cent Nerv Syst Dis"},{"key":"7471_CR135","doi-asserted-by":"crossref","first-page":"e33606","DOI":"10.1371\/journal.pone.0033606","volume":"7","author":"S Neselius","year":"2012","unstructured":"Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in olympic boxing: diagnosis and effects of repetitive head trauma. PLoS ONE. 2012;7:e33606.","journal-title":"PLoS ONE"},{"key":"7471_CR136","doi-asserted-by":"crossref","first-page":"116986","DOI":"10.1016\/j.jns.2020.116986","volume":"416","author":"S Mariotto","year":"2020","unstructured":"Mariotto S, Sechi E, Ferrari S. Serum neurofilament light chain studies in neurological disorders, hints for interpretation. J Neurol Sci. 2020;416:116986.","journal-title":"J Neurol Sci"},{"key":"7471_CR137","doi-asserted-by":"crossref","first-page":"758182","DOI":"10.3389\/fnins.2022.758182","volume":"16","author":"R Zanardini","year":"2022","unstructured":"Zanardini R, Saraceno C, Benussi L, Squitti R, Ghidoni R. Exploring neurofilament light chain and exosomes in the genetic forms of frontotemporal dementia. Front Neurosci. 2022;16:758182.","journal-title":"Front Neurosci"},{"key":"7471_CR138","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuint.2017.05.010","volume":"108","author":"S Lista","year":"2017","unstructured":"Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Cavedo E, Dos Santos AM, Epelbaum S, Lamari F, Dubois B, Floris R, Garaci F, Hampel H. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for alzheimer\u2019s disease. Neurochem Int. 2017;108:355\u201360.","journal-title":"Neurochem Int"},{"key":"7471_CR139","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1212\/WNL.0000000000004088","volume":"89","author":"D Alcolea","year":"2017","unstructured":"Alcolea D, Vilaplana E, Su\u00e1rez-Calvet M, Ill\u00e1n-Gala I, Blesa R, Clarim\u00f3n J, Llad\u00f3 A, S\u00e1nchez-Valle R, Molinuevo JL, Garc\u00eda-Ribas G, Compta Y, Mart\u00ed MJ, Pi\u00f1ol-Ripoll G, Amer-Ferrer G, Noguera A, Garc\u00eda-Mart\u00edn A, Fortea J, Lle\u00f3 A. CSF sAPP\u03b2, YKL-40, and neurofilament light in frontotemporal Lobar degeneration. Neurology. 2017;89:178\u201388.","journal-title":"Neurology"},{"key":"7471_CR140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2018.3459","volume":"76","author":"S Kern","year":"2019","unstructured":"Kern S, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Waern M, Hagen CE, van Harten AC, Knopman DS, Jack CR, Petersen RC, Mielke MM. Association of cerebrospinal fluid neurofilament light protein with risk of mild cognitive impairment among individuals without cognitive impairment. JAMA Neurol. 2019;76:187\u201393.","journal-title":"JAMA Neurol"},{"key":"7471_CR141","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet AL, Pascoal TA, Lle\u00f3 A, Parnetti L, Galimberti D, Bonanni L, Pilotto A, Padovani A, Lycke J, Novakova L, Axelsson M, Velayudhan L, Rabinovici GD, Miller B, Pariante C, Nikkheslat N, Resnick SM, Thambisetty M, Sch\u00f6ll M, Fern\u00e1ndez-Eulate G, Gil-Bea FJ, de L\u00f3pez A, Al-Chalabi A, Rosa-Neto P, Strydom A, Svenningsson P, Stomrud E, Santillo A, Aarsland D, van Swieten JC, Palmqvist S, Zetterberg H, Blennow K, Hye A, Hansson O. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400.","journal-title":"Nat Commun"},{"key":"7471_CR142","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall S, \u00d6hrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, H\u00e5kan W, Decraemer H, N\u00e5gga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders. Arch Neurol. 2012;69:1445\u201352.","journal-title":"Arch Neurol"},{"key":"7471_CR143","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.3390\/ijms25158354","volume":"25","author":"C Saraceno","year":"2024","unstructured":"Saraceno C, Cervellati C, Trentini A, Crescenti D, Longobardi A, Geviti A, Bonfiglio NS, Bellini S, Nicsanu R, Fostinelli S, Mola G, Riccetti R, Moretti DV, Zanetti O, Binetti G, Zuliani G, Ghidoni R. Serum Beta-Secretase 1 activity is a potential marker for the differential diagnosis between alzheimer\u2019s disease and frontotemporal dementia: A pilot study. Int J Mol Sci. 2024;25:8354.","journal-title":"Int J Mol Sci"},{"key":"7471_CR144","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12035-019-01698-3","volume":"57","author":"Z Alirezaei","year":"2020","unstructured":"Alirezaei Z, Pourhanifeh MH, Borran S, Nejati M, Mirzaei H, Hamblin MR. Neurofilament light chain as a Biomarker, and correlation with magnetic resonance imaging in diagnosis of CNS-Related disorders. Mol Neurobiol. 2020;57:469\u201391.","journal-title":"Mol Neurobiol"},{"key":"7471_CR145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.parkreldis.2009.07.007","volume":"16","author":"R Constantinescu","year":"2010","unstructured":"Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in parkinson\u2019s disease and atypical parkinsonian disorders. Parkinsonism Relat Disord. 2010;16:142\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"7471_CR146","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fneur.2015.00091","volume":"6","author":"MK Herbert","year":"2015","unstructured":"Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RAJ, Bloem BR, Kuiperij HB, Verbeek MM. CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. Front Neurol. 2015;6:91.","journal-title":"Front Neurol"},{"key":"7471_CR147","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mds.870130116","volume":"13","author":"B Holmberg","year":"1998","unstructured":"Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with parkinson\u2019s disease. Mov Disord. 1998;13:70\u20137.","journal-title":"Mov Disord"},{"key":"7471_CR148","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10072-016-2783-7","volume":"38","author":"X Hu","year":"2017","unstructured":"Hu X, Yang Y, Gong D. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to parkinson\u2019s disease: a meta-analysis. Neurol Sci. 2017;38:407\u201314.","journal-title":"Neurol Sci"},{"key":"7471_CR149","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2011.08.012","volume":"18","author":"S Bech","year":"2012","unstructured":"Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NHH, J\u00f8rgensen HL, Rosengren L, Blennow K, Zetterberg H, Winge K. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord. 2012;18:69\u201372.","journal-title":"Parkinsonism Relat Disord"},{"key":"7471_CR150","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K. Blood-based nfl: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88:930\u20137.","journal-title":"Neurology"},{"key":"7471_CR151","doi-asserted-by":"crossref","first-page":"e12168","DOI":"10.1002\/dad2.12168","volume":"13","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Su\u00e1rez-Calvet M, Karikari TK, Lantero-Rodriguez J, Snellman A, Sauer M, Simr\u00e9n J, Minguillon C, Fauria K, Blennow K, Zetterberg H. Effects of pre-analytical procedures on blood biomarkers for alzheimer\u2019s pathophysiology, glial activation, and neurodegeneration. Alzheimers Dement (Amst). 2021;13:e12168.","journal-title":"Alzheimers Dement (Amst)"},{"key":"7471_CR152","first-page":"e1479","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR, Otto M, Verbeek MM. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. 2019;92:e1479\u201386.","journal-title":"Neurology"},{"key":"7471_CR153","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40035-023-00342-4","volume":"12","author":"M Schmitz","year":"2023","unstructured":"Schmitz M, Candelise N, Canaslan S, Altmeppen HC, Matschke J, Glatzel M, Younas N, Zafar S, Hermann P. Zerr I: \u03b1-Synuclein conformers reveal link to clinical heterogeneity of \u03b1-synucleinopathies. Transl Neurodegener. 2023;12:12.","journal-title":"Transl Neurodegener"},{"key":"7471_CR154","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1007\/s00415-024-12647-z","volume":"271","author":"S Katzdobler","year":"2024","unstructured":"Katzdobler S, N\u00fcbling G, Klietz M, Fietzek UM, Palleis C, Bernhardt AM, Wegner F, Huber M, Rogozinski S, Schneider L, Spruth EJ, Beyle A, Vogt IR, Brandt M, Hansen N, Glanz W, Brockmann K, Spottke A, Hoffmann DC, Peters O, Priller J, Wiltfang J, D\u00fczel E, Schneider A, Falkenburger B, Klockgether T, Gasser T, Nuscher B, Haass C, H\u00f6glinger G, Levin J. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA). J Neurol. 2024;271:6991\u20139.","journal-title":"J Neurol"},{"key":"7471_CR155","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","volume":"95","author":"D B\u00e4ckstr\u00f6m","year":"2020","unstructured":"B\u00e4ckstr\u00f6m D, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, Forsgren L, Lenfeldt N. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology. 2020;95:e827\u201338.","journal-title":"Neurology"},{"key":"7471_CR156","doi-asserted-by":"crossref","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","volume":"8","author":"Y Lin","year":"2018","unstructured":"Lin Y, Lee W, Wang S, Fuh J. Levels of plasma neurofilament light chain and cognitive function in patients with alzheimer or Parkinson disease. Sci Rep. 2018;8:17368.","journal-title":"Sci Rep"},{"key":"7471_CR157","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2021.04.016","volume":"87","author":"A Pilotto","year":"2021","unstructured":"Pilotto A, Imarisio A, Conforti F, Scalvini A, Masciocchi S, Nocivelli S, Turrone R, Gipponi S, Cottini E, Borroni B, Rizzetti MC, Pizzi M, Bonanni L, Sturchio A, Espay AJ, Zetterberg H, Ashton NJ, Hye A, Padovani A. Plasma NfL, clinical subtypes and motor progression in parkinson\u2019s disease. Parkinsonism Relat Disord. 2021;87:41\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"7471_CR158","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","volume":"72","author":"MD Weingarten","year":"1975","unstructured":"Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975;72:1858\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7471_CR159","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1073\/pnas.73.11.4070","volume":"73","author":"GB Witman","year":"1976","unstructured":"Witman GB, Cleveland DW, Weingarten MD, Kirschner MW. Tubulin requires Tau for growth onto microtubule initiating sites. Proc Natl Acad Sci U S A. 1976;73:4070\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7471_CR160","first-page":"271","volume":"387","author":"RL Neve","year":"1986","unstructured":"Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubule-associated protein Tau and chromosomal localization of the genes for Tau and microtubule-associated protein 2. Brain Res. 1986;387:271\u201380.","journal-title":"Brain Res"},{"key":"7471_CR161","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.1504081112","volume":"112","author":"H Kadavath","year":"2015","unstructured":"Kadavath H, Hofele RV, Biernat J, Kumar S, Tepper K, Urlaub H, Mandelkow E, Zweckstetter M. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci U S A. 2015;112:7501\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7471_CR162","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1083\/jcb.101.4.1371","volume":"101","author":"LI Binder","year":"1985","unstructured":"Binder LI, Frankfurter A, Rebhun LI. The distribution of Tau in the mammalian central nervous system. J Cell Biol. 1985;101:1371\u20138.","journal-title":"J Cell Biol"},{"key":"7471_CR163","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1523\/JNEUROSCI.16-11-03601.1996","volume":"16","author":"MM Black","year":"1996","unstructured":"Black MM, Slaughter T, Moshiach S, Obrocka M, Fischer I. Tau is enriched on dynamic microtubules in the distal region of growing axons. J Neurosci. 1996;16:3601\u201319.","journal-title":"J Neurosci"},{"key":"7471_CR164","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"LM Ittner","year":"2010","unstructured":"Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W\u00f6lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G\u00f6tz J. Dendritic function of Tau mediates amyloid-beta toxicity in alzheimer\u2019s disease mouse models. Cell. 2010;142:387\u201397.","journal-title":"Cell"},{"key":"7471_CR165","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1523\/JNEUROSCI.4261-13.2014","volume":"34","author":"ML Frandemiche","year":"2014","unstructured":"Frandemiche ML, De Seranno S, Rush T, Borel E, Elie A, Arnal I, Lant\u00e9 F, Buisson A. Activity-dependent Tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J Neurosci. 2014;34:6084\u201397.","journal-title":"J Neurosci"},{"key":"7471_CR166","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neuron.2015.08.020","volume":"87","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Tseng I-, Heyser CJ, Rockenstein E, Mante M, Adame A, Zheng Q, Huang T, Wang X, Arslan PE, Chakrabarty P, Wu C, Bu G, Mobley WC, Zhang Y, St George-Hyslop P, Masliah E, Fraser P, Xu H. Appoptosin-Mediated caspase cleavage of Tau contributes to progressive supranuclear palsy pathogenesis. Neuron. 2015;87:963\u201375.","journal-title":"Neuron"},{"key":"7471_CR167","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","volume":"15","author":"T Guo","year":"2020","unstructured":"Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of alzheimer\u2019s disease. Mol Neurodegener. 2020;15:40.","journal-title":"Mol Neurodegener"},{"key":"7471_CR168","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in alzheimer disease. Nat Rev Neurol. 2010;6:131\u201344.","journal-title":"Nat Rev Neurol"},{"key":"7471_CR169","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A, Sch\u00f6ll M, Troakes C, Hye A, Gauthier S, Vanmechelen E, Zetterberg H, Rosa-Neto P, Blennow K. Plasma p-tau231: a new biomarker for incipient alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"7471_CR170","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, Gonz\u00e1lez-Ortiz F, Di Molfetta G, Meda FJ, Jonaitis EM, Koscik RL, Cody K, Betthauser TJ, Li Y, Vanmechelen E, Palmqvist S, Stomrud E, Bateman RJ, Zetterberg H, Johnson SC, Blennow K, Hansson O. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362.","journal-title":"Nat Med"},{"key":"7471_CR171","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Sch\u00f6ll M, Massarweh G, Soucy J, H\u00f6glund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K. Blood phosphorylated Tau 181 as a biomarker for alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"7471_CR172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2021.4222","volume":"79","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, Mollenhauer B, Pilotto A, Lemstra A, Paquet C, Abdelnour C, Kramberger MG, Bonanni L, Vandenberghe R, Hye A, Blennow K, Zetterberg H, Aarsland D. Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with lewy bodies. JAMA Neurol. 2022;79:1\u20136.","journal-title":"JAMA Neurol"},{"key":"7471_CR173","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mds.28370","volume":"36","author":"S Hall","year":"2021","unstructured":"Hall S, Janelidze S, Londos E, Leuzy A, Stomrud E, Dage JL, Hansson O. Plasma Phospho-Tau identifies alzheimer\u2019s Co-Pathology in patients with lewy body disease. Mov Disord. 2021;36:767\u201371.","journal-title":"Mov Disord"},{"key":"7471_CR174","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13195-024-01502-y","volume":"16","author":"A Vrillon","year":"2024","unstructured":"Vrillon A, Bousiges O, G\u00f6tze K, Demuynck C, Muller C, Ravier A, Schorr B, Philippi N, Hourregue C, Cognat E, Dumurgier J, Lilamand M, Cretin B, Blanc F, Paquet C. Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with lewy bodies. Alzheimers Res Ther. 2024;16:146.","journal-title":"Alzheimers Res Ther"},{"key":"7471_CR175","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","volume":"93","author":"L Chouliaras","year":"2022","unstructured":"Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, Savulich G, Prats-Sedano MA, Heslegrave AJ, Zetterberg H, Su L, Rowe JB, O\u2019Brien JT. Differential levels of plasma biomarkers of neurodegeneration in lewy body dementia, alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93:651\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7471_CR176","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","volume":"12","author":"N Chen","year":"2020","unstructured":"Chen N, Chen H, Li S, Chang Y, Chen M, Tsai N, Yu C, Yang S, Lu C, Lin W. Plasma levels of \u03b1-Synuclein, A\u03b2-40 and T-tau as biomarkers to predict cognitive impairment in parkinson\u2019s disease. Front Aging Neurosci. 2020;12:112.","journal-title":"Front Aging Neurosci"},{"key":"7471_CR177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-022-00384-x","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu L, Rota S, Hye A, Heslegrave A, Trivedi D, Gibson LL, Farrell C, Zinzalias P, Rizos A, Zetterberg H, Chaudhuri KR, Aarsland D. Plasma p-tau181, neurofilament light chain and association with cognition in parkinson\u2019s disease. Npj Parkinsons Dis. 2022;8:1\u20137.","journal-title":"Npj Parkinsons Dis"},{"key":"7471_CR178","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00401-011-0830-2","volume":"122","author":"I Mundi\u00f1ano","year":"2011","unstructured":"Mundi\u00f1ano I, Caballero M, Ord\u00f3\u00f1ez C, Hernandez M, DiCaudo C, Marcilla I, Erro M, Tu\u00f1on M, Luquin M. Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. Acta Neuropathol. 2011;122:61\u201374.","journal-title":"Acta Neuropathol"},{"key":"7471_CR179","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2990.2003.00453.x","volume":"29","author":"Y Tsuboi","year":"2003","unstructured":"Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson DW. Tau pathology in the olfactory bulb correlates with Braak stage, lewy body pathology and Apolipoprotein epsilon4. Neuropathol Appl Neurobiol. 2003;29:503\u201310.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"7471_CR180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/229","volume":"1","author":"S Hilfiker","year":"1998","unstructured":"Hilfiker S, Schweizer FE, Kao HT, Czernik AJ, Greengard P, Augustine GJ. Two sites of action for synapsin domain E in regulating neurotransmitter release. Nat Neurosci. 1998;1:29\u201335.","journal-title":"Nat Neurosci"},{"key":"7471_CR181","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pneurobio.2010.04.006","volume":"91","author":"F Cesca","year":"2010","unstructured":"Cesca F, Baldelli P, Valtorta F, Benfenati F. The synapsins: key actors of synapse function and plasticity. Prog Neurobiol. 2010;91:313\u201348.","journal-title":"Prog Neurobiol"},{"key":"7471_CR182","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.semcdb.2011.07.007","volume":"22","author":"B Porton","year":"2011","unstructured":"Porton B, Wetsel WC, Kao H. Synapsin III: role in neuronal plasticity and disease. Semin Cell Dev Biol. 2011;22:416\u201324.","journal-title":"Semin Cell Dev Biol"},{"key":"7471_CR183","doi-asserted-by":"crossref","first-page":"9762","DOI":"10.1523\/JNEUROSCI.2071-09.2010","volume":"30","author":"BM Kile","year":"2010","unstructured":"Kile BM, Guillot TS, Venton BJ, Wetsel WC, Augustine GJ, Wightman RM. Synapsins differentially control dopamine and serotonin release. J Neurosci. 2010;30:9762\u201370.","journal-title":"J Neurosci"},{"key":"7471_CR184","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1242\/jcs.157867","volume":"128","author":"M Zaltieri","year":"2015","unstructured":"Zaltieri M, Grigoletto J, Longhena F, Navarria L, Favero G, Castrezzati S, Colivicchi MA, Della Corte L, Rezzani R, Pizzi M, Benfenati F, Spillantini MG, Missale C, Spano P, Bellucci A. \u03b1-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. J Cell Sci. 2015;128:2231\u201343.","journal-title":"J Cell Sci"},{"key":"7471_CR185","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bpa.12587","volume":"28","author":"F Longhena","year":"2018","unstructured":"Longhena F, Faustini G, Varanita T, Zaltieri M, Porrini V, Tessari I, Poliani PL, Missale C, Borroni B, Padovani A, Bubacco L, Pizzi M, Spano P, Bellucci A. Synapsin III is a key component of \u03b1-synuclein fibrils in lewy bodies of PD brains. Brain Pathol. 2018;28:875\u201388.","journal-title":"Brain Pathol"},{"key":"7471_CR186","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00401-018-1892-1","volume":"136","author":"G Faustini","year":"2018","unstructured":"Faustini G, Longhena F, Varanita T, Bubacco L, Pizzi M, Missale C, Benfenati F, Bj\u00f6rklund A, Spano P, Bellucci A. Synapsin III deficiency hampers \u03b1-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of parkinson\u2019s disease. Acta Neuropathol. 2018;136:621\u201339.","journal-title":"Acta Neuropathol"},{"key":"7471_CR187","first-page":"3902","volume":"11","author":"G Faustini","year":"2022","unstructured":"Faustini G, Longhena F, Musc\u00f2 A, Bono F, Parrella E, La Via L, Barbon A, Pizzi M, Onofri F, Benfenati F, Missale C, Memo M, Zizioli D, Bellucci A, Synapsin. III Regulates Dopaminergic Neuron Dev Vertebrates Cells. 2022;11:3902.","journal-title":"III Regulates Dopaminergic Neuron Dev Vertebrates Cells"},{"key":"7471_CR188","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D\u2019Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7471_CR189","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","volume":"30","author":"M Colombo","year":"2014","unstructured":"Colombo M, Raposo G, Th\u00e9ry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255\u201389.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"7471_CR190","doi-asserted-by":"crossref","unstructured":"Y\u00e1\u00f1ez-M\u00f3 M, Siljander PR-, Andreu Z, Zavec AB, Borr\u00e0s FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Col\u00e1s E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NHH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Kr\u00e4mer-Albers E, Laitinen S, L\u00e4sser C, Lener T, Ligeti E, Lin\u0113 A, Lipps G, Llorente A, L\u00f6tvall J, Man\u010dek-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-\u2018t Hoen ENM, Nyman TA, O\u2019Driscoll L, Olivan M, Oliveira C, P\u00e1llinger \u00c9, Del Portillo HA, Revent\u00f3s J, Rigau M, Rohde E, Sammar M, S\u00e1nchez-Madrid F, Santar\u00e9m N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MHM, De Wever O. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.","DOI":"10.3402\/jev.v4.27066"},{"key":"7471_CR191","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/prca.200700522","volume":"1","author":"E Kr\u00e4mer-Albers","year":"2007","unstructured":"Kr\u00e4mer-Albers E, Bretz N, Tenzer S, Winterstein C, M\u00f6bius W, Berger H, Nave K, Schild H, Trotter J. Oligodendrocytes secrete exosomes containing major Myelin and stress-protective proteins: trophic support for axons? Proteom Clin Appl. 2007;1:1446\u201361.","journal-title":"Proteom Clin Appl"},{"key":"7471_CR192","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.nbd.2011.01.029","volume":"42","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJA, Cooper JM. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42:360\u20137.","journal-title":"Neurobiol Dis"},{"key":"7471_CR193","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41419-018-0816-2","volume":"9","author":"N Fussi","year":"2018","unstructured":"Fussi N, H\u00f6llerhage M, Chakroun T, Nyk\u00e4nen N, R\u00f6sler TW, Koeglsperger T, Wurst W, Behrends C, H\u00f6glinger GU. Exosomal secretion of \u03b1-synuclein as protective mechanism after upstream blockage of macroautophagy. Cell Death Dis. 2018;9:757.","journal-title":"Cell Death Dis"},{"key":"7471_CR194","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcdb.2015.02.007","volume":"40","author":"BM Coleman","year":"2015","unstructured":"Coleman BM, Hill AF. Extracellular vesicles\u2013Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases. Semin Cell Dev Biol. 2015;40:89\u201396.","journal-title":"Semin Cell Dev Biol"},{"key":"7471_CR195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1479-5876-10-5","volume":"10","author":"JM Street","year":"2012","unstructured":"Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, Chalmers RTA, Webb DJ, Dear JW. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med. 2012;10:5.","journal-title":"J Transl Med"},{"key":"7471_CR196","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neulet.2018.12.030","volume":"696","author":"Z Cao","year":"2019","unstructured":"Cao Z, Wu Y, Liu G, Jiang Y, Wang X, Wang Z, Feng T. \u03b1-Synuclein in salivary extracellular vesicles as a potential biomarker of parkinson\u2019s disease. Neurosci Lett. 2019;696:114\u201320.","journal-title":"Neurosci Lett"},{"key":"7471_CR197","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00401-021-02324-0","volume":"142","author":"S Dutta","year":"2021","unstructured":"Dutta S, Hornung S, Kruayatidee A, Maina KN, Del Rosario I, Paul KC, Wong DY, Duarte Folle A, Markovic D, Palma J, Serrano GE, Adler CH, Perlman SL, Poon WW, Kang UJ, Alcalay RN, Sklerov M, Gylys KH, Kaufmann H, Fogel BL, Bronstein JM, Ritz B. Bitan G: \u03b1-Synuclein in blood exosomes Immunoprecipitated using neuronal and oligodendroglial markers distinguishes parkinson\u2019s disease from multiple system atrophy. Acta Neuropathol. 2021;142:495\u2013511.","journal-title":"Acta Neuropathol"},{"key":"7471_CR198","first-page":"704678","volume":"2014","author":"DH Ho","year":"2014","unstructured":"Ho DH, Yi S, Seo H, Son I, Seol W. Increased DJ-1 in urine exosome of Korean males with parkinson\u2019s disease. Biomed Res Int. 2014;2014:704678.","journal-title":"Biomed Res Int"},{"key":"7471_CR199","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.gendis.2019.12.001","volume":"8","author":"Q Yuan","year":"2021","unstructured":"Yuan Q, Li X, Zhang S, Wang H, Wang Y. Extracellular vesicles in neurodegenerative diseases: insights and new perspectives. Genes Dis. 2021;8:124\u201332.","journal-title":"Genes Dis"},{"key":"7471_CR200","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jnc.15288","volume":"157","author":"JR Pinnell","year":"2021","unstructured":"Pinnell JR, Cui M, Tieu K. Exosomes in Parkinson disease. J Neurochem. 2021;157:413\u201328.","journal-title":"J Neurochem"},{"key":"7471_CR201","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/brain\/awv346","volume":"139","author":"A Stuendl","year":"2016","unstructured":"Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A. Induction of \u03b1-synuclein aggregate formation by CSF exosomes from patients with parkinson\u2019s disease and dementia with lewy bodies. Brain. 2016;139:481\u201394.","journal-title":"Brain"},{"key":"7471_CR202","first-page":"e2332","volume":"96","author":"Z Hong","year":"2021","unstructured":"Hong Z, Tian C, Stewart T, Aro P, Soltys D, Bercow M, Sheng L, Borden K, Khrisat T, Pan C, Zabetian CP, Peskind ER, Quinn JF, Montine TJ, Aasly J, Shi M, Zhang J. Development of a sensitive diagnostic assay for Parkinson disease quantifying \u03b1-Synuclein-Containing. Extracell Vesicles Neurology. 2021;96:e2332\u201345.","journal-title":"Extracell Vesicles Neurology"},{"key":"7471_CR203","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","volume":"128","author":"M Shi","year":"2014","unstructured":"Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C, Li Y, Aro P, Dator R, He C, Hipp MJ, Zabetian CP, Peskind ER, Hu S, Quinn JF, Galasko DR, Banks WA, Zhang J. Plasma Exosomal \u03b1-synuclein is likely CNS-derived and increased in parkinson\u2019s disease. Acta Neuropathol. 2014;128:639\u201350.","journal-title":"Acta Neuropathol"},{"key":"7471_CR204","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jalz.2016.04.003","volume":"12","author":"M Shi","year":"2016","unstructured":"Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu S, Quinn JF, Galasko DR, Montine TJ, Banks WA, Zhang J. CNS Tau efflux via exosomes is likely increased in parkinson\u2019s disease but not in alzheimer\u2019s disease. Alzheimers Dement. 2016;12:1125\u201331.","journal-title":"Alzheimers Dement"},{"key":"7471_CR205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fncel.2018.00125","volume":"12","author":"S Cerri","year":"2018","unstructured":"Cerri S, Ghezzi C, Sampieri M, Siani F, Avenali M, Dornini G, Zangaglia R, Minafra B, Blandini F. The Exosomal\/Total \u03b1-Synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients. Front Cell Neurosci. 2018;12:125.","journal-title":"Front Cell Neurosci"},{"key":"7471_CR206","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/ene.14208","volume":"27","author":"M Niu","year":"2020","unstructured":"Niu M, Li Y, Li G, Zhou L, Luo N, Yao M, Kang W, Liu J. A longitudinal study on \u03b1-synuclein in plasma neuronal exosomes as a biomarker for parkinson\u2019s disease development and progression. Eur J Neurol. 2020;27:967\u201374.","journal-title":"Eur J Neurol"},{"key":"7471_CR207","doi-asserted-by":"crossref","unstructured":"Yu Z, Shi M, Stewart T, Fernagut P, Huang Y, Tian C, Dehay B, Atik A, Yang D, De Giorgi F, Ichas F, Canron M, Ceravolo R, Frosini D, Kim H, Feng T, Meissner WG, Zhang J. Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. Brain. 2020;143:1780\u201397.","DOI":"10.1093\/brain\/awaa110"},{"key":"7471_CR208","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/NXI.0000000000000866","volume":"7","author":"E Vacchi","year":"2020","unstructured":"Vacchi E, Burrello J, Di Silvestre D, Burrello A, Bolis S, Mauri P, Vassalli G, Cereda CW, Farina C, Barile L, Kaelin-Lang A, Melli G. Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease. Neurol Neuroimmunol Neuroinflamm. 2020;7:e866.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"7471_CR209","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.parkreldis.2018.11.021","volume":"61","author":"T Ohmichi","year":"2019","unstructured":"Ohmichi T, Mitsuhashi M, Tatebe H, Kasai T, Ali El-Agnaf OM, Tokuda T. Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose parkinson\u2019s and related diseases. Parkinsonism Relat Disord. 2019;61:82\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"7471_CR210","doi-asserted-by":"crossref","first-page":"667369","DOI":"10.3389\/fcell.2021.667369","volume":"9","author":"A Longobardi","year":"2021","unstructured":"Longobardi A, Benussi L, Nicsanu R, Bellini S, Ferrari C, Saraceno C, Zanardini R, Catania M, Di Fede G, Squitti R, Binetti G, Ghidoni R. Plasma extracellular vesicle size and concentration are altered in alzheimer\u2019s Disease, dementia with lewy Bodies, and frontotemporal dementia. Front Cell Dev Biol. 2021;9:667369.","journal-title":"Front Cell Dev Biol"},{"key":"7471_CR211","first-page":"462","volume":"11","author":"A Longobardi","year":"2022","unstructured":"Longobardi A, Nicsanu R, Bellini S, Squitti R, Catania M, Tiraboschi P, Saraceno C, Ferrari C, Zanardini R, Binetti G, Di Fede G, Benussi L, Ghidoni R. Cerebrospinal fluid EV concentration and size are altered in alzheimer\u2019s disease and dementia with. Lewy Bodies Cells. 2022;11:462.","journal-title":"Lewy Bodies Cells"},{"key":"7471_CR212","doi-asserted-by":"crossref","first-page":"149620","DOI":"10.1016\/j.bbrc.2024.149620","volume":"703","author":"Y Ishiguro","year":"2024","unstructured":"Ishiguro Y, Tsunemi T, Shimada T, Yoroisaka A, Ueno S, Takeshige-Amano H, Hatano T, Inoue Y, Saiki S, Hattori N. Extracellular vesicles contain filamentous alpha-synuclein and facilitate the propagation of parkinson\u2019s pathology. Biochem Biophys Res Commun. 2024;703:149620.","journal-title":"Biochem Biophys Res Commun"},{"key":"7471_CR213","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/mds.26686","volume":"31","author":"KB Fraser","year":"2016","unstructured":"Fraser KB, Rawlins AB, Clark RG, Alcalay RN, Standaert DG, Liu N, West AB. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic parkinson\u2019s disease. Mov Disord. 2016;31:1543\u201350.","journal-title":"Mov Disord"},{"key":"7471_CR214","doi-asserted-by":"crossref","first-page":"1250832","DOI":"10.3389\/fneur.2023.1250832","volume":"14","author":"S Roy","year":"2023","unstructured":"Roy S, Kashyap NN, Anchan AS, Punja D, Jasti DB, Upadhya D. Urinary extracellular vesicle dynamics in parkinson\u2019s disease patients with urinary dysfunction. Front Neurol. 2023;14:1250832.","journal-title":"Front Neurol"},{"key":"7471_CR215","doi-asserted-by":"crossref","first-page":"e2408949121","DOI":"10.1073\/pnas.2408949121","volume":"121","author":"T Gilboa","year":"2024","unstructured":"Gilboa T, Ter-Ovanesyan D, Wang S, Whiteman S, Kannarkat GT, Church GM, Chen-Plotkin AS, Walt DR. Measurement of \u03b1-synuclein as protein cargo in plasma extracellular vesicles. Proc Natl Acad Sci U S A. 2024;121:e2408949121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7471_CR216","doi-asserted-by":"crossref","first-page":"577089","DOI":"10.1016\/j.jneuroim.2019.577089","volume":"338","author":"K Chatterjee","year":"2020","unstructured":"Chatterjee K, Roy A, Banerjee R, Choudhury S, Mondal B, Halder S, Basu P, Shubham S, Dey S, Kumar H. Inflammasome and \u03b1-synuclein in parkinson\u2019s disease: A cross-sectional study. J Neuroimmunol. 2020;338:577089.","journal-title":"J Neuroimmunol"},{"key":"7471_CR217","first-page":"121ra20","volume":"4","author":"Y Wang","year":"2012","unstructured":"Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM-, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J. Phosphorylated \u03b1-synuclein in parkinson\u2019s disease. Sci Transl Med. 2012;4:121ra20.","journal-title":"Sci Transl Med"},{"key":"7471_CR218","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3389\/fneur.2020.01043","volume":"11","author":"Z Cao","year":"2020","unstructured":"Cao Z, Wu Y, Liu G, Jiang Y, Wang X, Wang Z, Feng T. Differential diagnosis of multiple system Atrophy-Parkinsonism and parkinson\u2019s disease using \u03b1-Synuclein and external anal sphincter electromyography. Front Neurol. 2020;11:1043.","journal-title":"Front Neurol"},{"key":"7471_CR219","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/brainsci11010119","volume":"11","author":"VC Constantinides","year":"2021","unstructured":"Constantinides VC, Majbour NK, Paraskevas GP, Abdi I, Safieh-Garabedian B, Stefanis L, El-Agnaf OM, Kapaki E. Cerebrospinal fluid \u03b1-Synuclein species in cognitive and movements disorders. Brain Sci. 2021;11:119.","journal-title":"Brain Sci"},{"key":"7471_CR220","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.111","volume":"33","author":"I van Steenoven","year":"2018","unstructured":"van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW. El-Agnaf OMA: \u03b1-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Mov Disord. 2018;33:1724\u201333.","journal-title":"Mov Disord"},{"key":"7471_CR221","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","volume":"99","author":"M Zubelzu","year":"2022","unstructured":"Zubelzu M, Morera-Herreras T, Irastorza G, G\u00f3mez-Esteban JC, Murueta-Goyena A. Plasma and serum alpha-synuclein as a biomarker in parkinson\u2019s disease: A meta-analysis. Parkinsonism Relat Disord. 2022;99:107\u201315.","journal-title":"Parkinsonism Relat Disord"},{"key":"7471_CR222","doi-asserted-by":"crossref","first-page":"e70167","DOI":"10.1111\/ene.70167","volume":"32","author":"CC Pedersen","year":"2025","unstructured":"Pedersen CC, Alves G, Tysnes O, Maple-Gr\u00f8dem J, Lange J. Cerebrospinal fluid phosphorylated Alpha-Synuclein in newly diagnosed parkinson\u2019s disease. Eur J Neurol. 2025;32:e70167.","journal-title":"Eur J Neurol"},{"key":"7471_CR223","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5607\/en20042","volume":"29","author":"W Seol","year":"2020","unstructured":"Seol W, Kim H, Son I. Urinary biomarkers for neurodegenerative diseases. Exp Neurobiol. 2020;29:325.","journal-title":"Exp Neurobiol"},{"key":"7471_CR224","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2021","unstructured":"Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, Trenkwalder C, Sixel-D\u00f6ring F, Foubert-Samier A, Pavy-Le Traon A, Plazzi G, Biscarini F, Montplaisir J, Gagnon J, Postuma RB, Antelmi E, Meissner WG, Mollenhauer B, Ben-Shlomo Y, Hu MT, Parkkinen L. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain. 2021;145:584\u201395.","journal-title":"Brain"},{"key":"7471_CR225","doi-asserted-by":"crossref","unstructured":"Kon\u00ed\u010dkov\u00e1 D, Hrabo\u0161 D, Men\u0161\u00edkov\u00e1 K, Tu\u010dkov\u00e1 L, Kaleta M, Strnad M, Colosimo C, Ka\u0148ovsk\u00fd P. RT-QuIC: a highly promising diagnostic method for neurodegenerative diseases\u2014advantages and limitations. Front Neurol. 2025;16.","DOI":"10.3389\/fneur.2025.1636086"},{"key":"7471_CR226","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/acn3.51280","volume":"8","author":"CD Orr\u00f9","year":"2021","unstructured":"Orr\u00f9 CD, Ma TC, Hughson AG, Groveman BR, Srivastava A, Galasko D, Angers R, Downey P, Crawford K, Hutten SJ, Kang UJ, Caughey B. A rapid \u03b1-synuclein seed assay of parkinson\u2019s disease CSF panel shows high diagnostic accuracy. Ann Clin Transl Neurol. 2021;8:374\u201384.","journal-title":"Ann Clin Transl Neurol"},{"key":"7471_CR227","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ane.12247","volume":"130","author":"N Malek","year":"2014","unstructured":"Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, Grosset DG. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for parkinson\u2019s disease - a systematic review. Acta Neurol Scand. 2014;130:59\u201372.","journal-title":"Acta Neurol Scand"},{"key":"7471_CR228","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.1002\/alz.14278","volume":"20","author":"D Eratne","year":"2024","unstructured":"Eratne D, Kang MJY, Lewis C, Dang C, Malpas CB, Keem M, Grewal J, Marinov V, Coe A, Kaylor-Hughes C, Borchard T, Keng-Hong C, Waxmann A, Saglam B, Kalincik T, Kanaan R, Kelso W, Evans A, Farrand S, Loi S, Walterfang M, Stehmann C, Li Q, Collins S, Masters CL, Santillo AF, Zetterberg H, Blennow K, Berkovic SF, Velakoulis D. Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting. Alzheimers Dement. 2024;20:7989\u20138001.","journal-title":"Alzheimers Dement"},{"key":"7471_CR229","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1093\/brain\/awac253","volume":"145","author":"V Chelban","year":"2022","unstructured":"Chelban V, Nikram E, Perez-Soriano A, Wilke C, Foubert-Samier A, Vijiaratnam N, Guo T, Jabbari E, Olufodun S, Gonzalez M, Senkevich K, Laurens B, P\u00e9ran P, Rascol O, Le Traon AP, Todd EG, Costantini AA, Alikhwan S, Tariq A, Ng BL, Mu\u00f1oz E, Painous C, Compta Y, Junque C, Segura B, Zhelcheska K, Wellington H, Sch\u00f6ls L, Jaunmuktane Z, Kobylecki C, Church A, Hu MTM, Rowe JB, Leigh PN, Massey L, Burn DJ, Pavese N, Foltynie T, Pchelina S, Wood N, Heslegrave AJ, Zetterberg H, Bocchetta M, Rohrer JD, Marti MJ, Synofzik M, Morris HR, Meissner WG, Houlden H. Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain. 2022;145:4398\u2013408.","journal-title":"Brain"},{"key":"7471_CR230","doi-asserted-by":"crossref","first-page":"1034684","DOI":"10.3389\/fnagi.2022.1034684","volume":"14","author":"C Delaby","year":"2022","unstructured":"Delaby C, Bousiges O, Bouvier D, Fill\u00e9e C, Fourier A, Mond\u00e9sert E, Nezry N, Omar S, Quadrio I, Rucheton B, Schraen-Maschke S, van Pesch V, Vicca S, Lehmann S, Bedel A. Neurofilaments contribution in clinic: state of the Art. Front Aging Neurosci. 2022;14:1034684.","journal-title":"Front Aging Neurosci"},{"key":"7471_CR231","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ana.25392","volume":"85","author":"D Coughlin","year":"2019","unstructured":"Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D, McMillan CT, Wolk DA, Akhtar RS, Hurtig HI, Branch Coslett H, Hamilton RH, Siderowf AD, Duda JE, Rascovsky K, Lee EB, Lee VM-, Grossman M, Trojanowski JQ, Irwin DJ. Cognitive and pathological influences of Tau pathology in lewy body disorders. Ann Neurol. 2019;85:259\u201371.","journal-title":"Ann Neurol"},{"key":"7471_CR232","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.3390\/ijms25136882","volume":"25","author":"CM Cristiani","year":"2024","unstructured":"Cristiani CM, Scaramuzzino L, Quattrone A, Parrotta EI, Cuda G, Quattrone A. Serum oligomeric \u03b1-Synuclein and p-tau181 in progressive supranuclear palsy and parkinson\u2019s disease. Int J Mol Sci. 2024;25:6882.","journal-title":"Int J Mol Sci"},{"key":"7471_CR233","doi-asserted-by":"crossref","first-page":"101999","DOI":"10.1016\/j.xcrm.2025.101999","volume":"6","author":"S Yan","year":"2025","unstructured":"Yan S, Zhang W, Li X, Dutta S, Castle AR, Liu Y, Sahoo A, Lam CL, Gatford NJF, Hu MT, Li C, Jiang C, Shu B, Tofaris GK. Single extracellular vesicle detection assay identifies membrane-associated \u03b1-synuclein as an early-stage biomarker in parkinson\u2019s disease. Cell Rep Med. 2025;6:101999.","journal-title":"Cell Rep Med"},{"key":"7471_CR234","doi-asserted-by":"crossref","first-page":"e0264446","DOI":"10.1371\/journal.pone.0264446","volume":"17","author":"F Lucien","year":"2022","unstructured":"Lucien F, Benarroch EE, Mullan A, Ali F, Boeve BF, Mielke MM, Petersen RC, Kim Y, Stang C, Camerucci E, Ross OA, Wszolek ZK, Knopman D, Bower J, Singer W, Savica R. Poly (ADP-Ribose) and \u03b1-synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE. 2022;17:e0264446.","journal-title":"PLoS ONE"},{"key":"7471_CR235","doi-asserted-by":"crossref","first-page":"e12383","DOI":"10.1002\/jev2.12383","volume":"12","author":"Y Hirschberg","year":"2023","unstructured":"Hirschberg Y, Valle-tamayo N, Dols\u2010icardo O, Engelborghs S, Buelens B, Vandenbroucke RE, Vermeiren Y, Boonen K, Mertens I. Proteomic comparison between non\u2010purified cerebrospinal fluid and cerebrospinal fluid\u2010derived extracellular vesicles from patients with Alzheimer\u2019s, parkinson\u2019s and lewy body dementia. J Extracell Vesicle. 2023;12:e12383.","journal-title":"J Extracell Vesicle"},{"key":"7471_CR236","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s44400-024-00002-y","volume":"1","author":"HB Taha","year":"2025","unstructured":"Taha HB. Alzheimer\u2019s disease and related dementias diagnosis: a biomarkers meta-analysis of general and CNS extracellular vesicles. Npj Dement. 2025;1:3.","journal-title":"Npj Dement"},{"key":"7471_CR237","doi-asserted-by":"crossref","unstructured":"Chang K, Liu K, Lai C, Yang S, Chen C. Assessing plasma levels of \u03b1-Synuclein and neurofilament light chain by different blood preparation methods. Front Aging Neurosci. 2021;13.","DOI":"10.3389\/fnagi.2021.759182"},{"key":"7471_CR238","doi-asserted-by":"crossref","first-page":"105358","DOI":"10.1016\/j.neuint.2022.105358","volume":"158","author":"H Tsao","year":"2022","unstructured":"Tsao H, Huang C, Wu Y. Detection and assessment of alpha-synuclein in Parkinson disease. Neurochem Int. 2022;158:105358.","journal-title":"Neurochem Int"},{"key":"7471_CR239","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/cells9020370","volume":"9","author":"K Barkovits","year":"2020","unstructured":"Barkovits K, Kruse N, Linden A, T\u00f6nges L, Pfeiffer K, Mollenhauer B, Marcus K. Blood contamination in CSF and its impact on quantitative analysis of Alpha-Synuclein. Cells. 2020;9:370.","journal-title":"Cells"},{"key":"7471_CR240","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","volume":"7","author":"C Barro","year":"2020","unstructured":"Barro C, Chitnis T, Weiner HL. Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol. 2020;7:2508.","journal-title":"Ann Clin Transl Neurol"},{"key":"7471_CR241","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1007\/s12035-023-03867-x","volume":"61","author":"J Yang","year":"2024","unstructured":"Yang J, Shen N, Shen J, Yang Y, Li H. Complicated role of Post-translational modification and Protease-Cleaved fragments of Tau in alzheimer\u2019s disease and other tauopathies. Mol Neurobiol. 2024;61:4712\u201331.","journal-title":"Mol Neurobiol"},{"key":"7471_CR242","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13195-020-00648-9","volume":"12","author":"KH Shim","year":"2020","unstructured":"Shim KH, Kang MJ, Suh JW, Pyun J, Ryoo N, Park YH, Youn YC, Jang J, Jeong JH, Park KW, Choi SH, Suk K, Lee H, Ko P, Lee C, Lim T, An SSA, Kim S. CSF total Tau\/\u03b1-synuclein ratio improved the diagnostic performance for alzheimer\u2019s disease as an indicator of Tau phosphorylation. Alzheimers Res Ther. 2020;12:83.","journal-title":"Alzheimers Res Ther"},{"key":"7471_CR243","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40035-023-00346-0","volume":"12","author":"HB Taha","year":"2023","unstructured":"Taha HB, Hornung S, Dutta S, Fenwick L, Lahgui O, Howe K, Elabed N, del Rosario I, Wong DY, Duarte Folle A, Markovic D, Palma J, Kang UJ, Alcalay RN, Sklerov M, Kaufmann H, Fogel BL, Bronstein JM, Ritz B, Bitan G. Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of parkinson\u2019s disease and multiple system atrophy. Translational Neurodegeneration. 2023;12:14.","journal-title":"Translational Neurodegeneration"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07471-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T20:02:44Z","timestamp":1767470564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07471-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":243,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7471"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07471-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}